Dmitry V Petrochenko

Dmitry V Petrochenko


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in Zavodskaya Laboratoriya. Diagnostika Materialov
Verified
Journal Article
Open access
PDF file
VGV. G. Garanin
V. G. Garanin
ONO. A. Neklyudov
O. A. Neklyudov
DPDmitry V Petrochenko
Dmitry V Petrochenko
ZSZ. V. Semenov
Z. V. Semenov
SPS. V. Pankratov
S. V. Pankratov
PVP. V. Vashchenko
P. V. Vashchenko
«Atom» software is used in integrated spectral devices for atomic emission and atomic absorption analysis produced by «VMK-Optoélektronika». Development of the new spectral instruments and upgrading of existing devices, birth of new mathematical methods and algorithms for processing spectral information, as well as user stories motivate and promote improvement of the software. This paper presents the main developments and most noticeable changes in «Atom «software for the period 2017 – 2018. The developed 64-bit version of «Atom» software removed the limitation on the amount of recorded sequences of spectra and significantly speeded up their processing by parallelizing the calculations on the processor cores (rather important step, for example, in scintillation atomic emission spectrometry). To implement continuum source electrothermal atomic absorption spectrometry for simultaneous multi-element analysis, we have developed the «Automatic Dispenser» and «Absorption Spectrometer» tools and have implemented the method proposed by D.A. Katskov to linearize calibration dependences in a wide range of concentrations. The possibility of spectrophotometric determination of substances in the solutions of their mixtures has been also implemented. The «Barcode Scanner» and the «Automatic Start of Measurement» tools have been developed to speed up and automate the analysis procedure. The software is supplemented with a set of useful functions designed for further development of analytical methods and programs of analysis.

23 February 2023 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ISIrina Stanoevich
Irina Stanoevich
VKV. V. Khvostovoy
V. V. Khvostovoy
ETE. I. Tishina
E. I. Tishina
VDV. I. Dyachkova
V. I. Dyachkova
DPDmitry V Petrochenko
Dmitry V Petrochenko
ISIrina Vasil’evna Stanoevich
Irina Vasil’evna Stanoevich
Purpose. To reflect the current understanding of the frequency, molecular mechanisms, and means of overcoming alopecia in cancer patients, taking into account the fundamental data of recent years on the physiology of the hair follicle and the pharmacological profile of the toxicity of anticancer drugs.Material and Methods. A literature search using Medline, Pubmed, etc. databases was carried out. More than 200 publications devoted to the study of alopecia were found, of which 42 were included in this review.Results. Chemotherapy-induced hair loss is a common adverse effect in cancer patients undergoing treatment. The frequency and molecular mechanism of the development of alopecia are related to the pharmacological features of the drug-based treatments, initial nutritional premorbid status, and predisposing polymorphisms of genes involved in drug conversion and excretion. Focal or diffuse alopecia may be the first sign of malignant growth within the paraneoplastic syndrome, primary or metastatic malignancies of the scalp, or be a manifestation of nutritional insufficiency. Baldness negatively affects the psycho-emotional state of patients, exacerbating depressive disorders, anxiety, reducing self-esteem and adherence to treatment. Thus, prevention or rapid overcoming of alopecia can significantly improve the quality of life of cancer patients. The use of scalp cooling or ‘cold caps’ is proven to be an effective way of combating chemotherapy-induced hair loss.Conclusion. Further studies are needed to prevent and treat alopecia in cancer patients.

8 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ISIrina Vasil’evna Stanoevich
Irina Vasil’evna Stanoevich
DPDmitry V Petrochenko
Dmitry V Petrochenko
ISIrina Stanoevich
Irina Stanoevich
EPEkaterina Pismennaya
Ekaterina Pismennaya
Background. The aim of this study was to develop a predictive model of anticancer drug therapy toxicity in patients with gastric cancer. Methods. The retrospective study included 100 patients with stage II–IV gastric cancer who underwent 4 chemotherapy cycles. Initial significant toxicity factors included age, gender, height, body mass, body mass index, disease stage, skeletal muscle index (SMI), as well as plasma levels of trace elements (copper, zinc, selenium, manganese) and thyroid-stimulating hormone, cancer histology type and treatment regimen. The CTCAE v5.0 scale was employed to assess the severity of adverse events. Statistical analysis and building of mathematical neural network models were carried out in SPSS Statistics (v19.0). Results. Lower SMI values were associated with higher rates of toxicity-related complications of anticancer drug therapy (p < 0.05): leukopenia, hypoproteinemia, nausea, vomiting, cardiovascular events. Anemia, thrombocytopenia, hepatic cytolysis syndrome, nausea, diarrhea, constipation and stomatitis showed a weaker correlation with SMI. An increase in TSH was associated with higher rates of thrombocytopenia, nausea and vomiting. A decrease in Cu/Zn in plasma correlated with the severity of leukopenia and diarrhea, whereas Se/Mn showed an inverse correlation with the severity of anemia. Conclusions. Sarcopenia, abnormal thyroid status and imbalances in copper, zinc, selenium and manganese in blood plasma of patients with gastric cancer may be used as predictors of increased toxicity of anticancer drug therapy.

8 May 2026 in Voprosy onkologii
Verified
Journal Article
Open access
DPDmitry V Petrochenko
Dmitry V Petrochenko
ISIrina Stanoevich
Irina Stanoevich
Введение. Нежелательные явления противоопухолевой терапии при раке желудка остаются серьезной клинической проблемой, ограничивающей проведение полного курса лечения. Нарушение микроэлементного баланса может способствовать развитию токсических осложнений и рассматриваться как возможная основа для персонализации терапии. Цель. Оценить связь между концентрацией меди, цинка, селена и марганца в плазме крови и частотой развития, характером и степенью тяжести токсических осложнений противоопухолевой лекарственной терапии у больных местнораспространенным и метастатическим раком желудка. Материалы и методы. В исследование включено 100 пациентов с впервые установленным диагнозом «рак желудка», прошедших четыре курса химиотерапии. Концентрации микроэлементов измерялись методом масс-спектрометрии с индуктивно-связанной плазмой (Varian 810-MS) непосредственно до проведения первого и пятого курса противоопухолевой лекарственной терапии. Тяжесть нежелательных явлений оценивалась по шкале CTCAE v5.0. Статистический анализ включал корреляцию Спирмена. Результаты. Абсолютные концентрации микроэлементов (меди, цинка, селена, марганца) в плазме крови больных раком желудка до первого и пятого курса химиотерапии не выходили за пределы референсных значений и слабо коррелировали с частотой, характером и степенью тяжести нежелательных явлений противоопухолевого лекарственного лечения (p > 0,05). Однако соотношения плазменных концентраций микроэлементов продемонстрировали значимые корреляции: соотношение медь/цинк до лечения коррелировало со снижением тяжести лейкопении (r = –0,331; p = 0,046) и диареи (r = –0,331; p = 0,001); соотношение селен/марганец до лечения ассоциировалось с уменьшением выраженности анемии (r = –0,211; p = 0,036); соотношения медь/марганец до лечения, цинк/селен до лечения и медь/цинк после четырех курсов химиотерапии показали обратные связи с диареей (r = –0,206, r = –0,199, r = –0,241 соответственно; p < 0,05). Заключение. Полученные результаты свидетельствуют о том, что предиктивной значимостью обладают не абсолютные концентрации исследованных микроэлементов в плазме крови больных до и в процессе лечения, а их соотношения. Полученные данные указывают на перспективность использования микроэлементных соотношений в многофакторных предиктивных моделях токсичности, где они могут выступать в качестве дополнительных и значимых маркеров наравне с генетическими, клинико–лабораторными и инструментальными предикторами.

19 August 2025 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
DPDmitry V Petrochenko
Dmitry V Petrochenko
DBD.A. Bereznikova
D.A. Bereznikova
FPF.V. Podolsky
F.V. Podolsky
IAI.E. Alekseev
I.E. Alekseev
AKA.D. Kondrashkina
A.D. Kondrashkina
ISIrina Vasil’evna Stanoevich
Irina Vasil’evna Stanoevich
Objective. To assess the relationship between skeletal muscle index (SMI) and the frequency, nature, and severity of toxic complications in patients with locally advanced and metastatic gastric cancer during antitumor drug therapy, a study is being conducted Material and methods. The study included 100 patients diagnosed with gastric cancer who had undergone four courses of chemotherapy. Computed tomography was used for sarcopenia diagnosis. SMI was calculated as the ratio of the average skeletal muscle area at the L3 level to the square of the patient’s height. The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 scale was used to assess the severity of adverse events. Results. Correlation analysis showed a moderate, inverse, statistically significant relationship (p<0.05) between SMI before treatment and the severity of anemia and vomiting after the fourth course of chemotherapy (r=–0.302; r=–0.331). A moderate, inverse relationship (p<0.05) was observed between SMI and the severity of anemia, vomiting (r=–0.323; r=–0.397), and hypoproteinemia (r=–0.300) after four courses of chemotherapy. SMI before treatment correlated weakly (p0.05) with SMI before treatment and after four courses of chemotherapy. Conclusion. The presence of sarcopenia in patients with gastric cancer may serve as a predictor of an increase in the severity of toxicity of antitumor drug therapy. The routinely used bode mass index and body surface area during treatment are not reliable markers for predicting toxicity.

15 November 2024 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ISIrina Stanoevich
Irina Stanoevich
VKV. V. Khvostovoy
V. V. Khvostovoy
DPDmitry V Petrochenko
Dmitry V Petrochenko
ASA. Yu. Salamatina
A. Yu. Salamatina
VIVitaliy Ioutsi
Vitaliy Ioutsi
IEI. V. Ermilov
I. V. Ermilov
The purpose of the study was to carry out a systematic analysis of the data available in the modern literature on the essentiality of selenium in biological systems and the importance of selenoproteins in oncogenesis.Material and Methods. The publications were analyzed using Scopus (415), PubMed (521), Web of Science (139), eLibrary.ru (240) databases. To obtain full-text documents, the electronic resources PubMed Central (PMC), Science Direct, Research Gate, eLibrary.ru were used.Results. The need to use selenium compounds for the prevention and treatment of malignant neoplasms is controversial, and some selenoproteins have demonstrated a permissive role in oncogenesis, thus requiring further in-depth study in neoplasms of various histogenesis.Conclusion. It is necessary to continue comprehensive molecular studies of bioorganic selenium compounds at the morphological, ultrastructural and biochemical levels in tumors of various localizations, depending on the genetic characteristics of the studied population and the geochemical characteristics of the region.